GLP-1 Family advanced
Oral Semaglutide Development History
Development history and formulation science behind oral semaglutide including SNAC technology.
By Encyclopeptide Editorial | 1 min read
semaglutide oral development SNAC formulation
Development Timeline
| Year | Milestone |
|---|---|
| 1999 | SNAC discovery for peptide absorption |
| 2008 | Proof of concept: oral GLP-1 absorption |
| 2015 | PIONEER program initiated |
| 2019 | FDA approval of Rybelsus |
Formulation Science
SNAC Technology
- Creates localized pH microenvironment
- Transient gastric cell swelling
- Enhanced paracellular semaglutide transport
Clinical Results
- PIONEER 6: Non-inferior cardiovascular safety
- HbA1c reduction: 1.0-1.4% (14 mg dose)
Chemical Identity
| Property | Value |
|---|---|
| Name | Oral Semaglutide Development History |
| Category | GLP-1 Family |
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Oral Semaglutide Development History” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Oral Semaglutide Development History with interactive quizzes on Wikipept.
Take a Quiz on Wikipept